http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 11 Aug 2026 16:35:53 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Equity+Offerings/Apollomics+announces+%2410M+private+placement+of+Class+A+shares/26906445.html <p>Apollomics Inc. (NASDAQ: APLM) has entered into definitive subscription agreements for a private placement of approximately $10.0 million, with closing expected on or about Aug. 14, 2026, subject to customary closing conditions.</p> <p>The transaction involves the issuance of up to 700,001 Class A ordinary shares at a par value of $0.01 per share, structured in two tranches. The first tranche consists of cash subscriptions for 533,334 Class A shares at $15.00 per share, generating approximately $8.0 million in gross cash proceeds before fees and expenses. The second tranche involves the automatic conversion of a $2.0 million unsecured convertible promissory note, dated http://www.streetinsider.com/Equity+Offerings/Apollomics+announces+%2410M+private+placement+of+Class+A+shares/26906445.html Tue, 11 Aug 2026 16:35:53 -0400 APLM APLMW O.53171576 http://www.streetinsider.com/Equity+Offerings/Apollomics+announces+%2410M+private+placement+of+Class+A+shares/26906445.html <p>Apollomics Inc. (NASDAQ: APLM) has entered into definitive subscription agreements for a private placement of approximately $10.0 million, with closing expected on or about Aug. 14, 2026, subject to customary closing conditions.</p> <p>The transaction involves the issuance of up to 700,001 Class A ordinary shares at a par value of $0.01 per share, structured in two tranches. The first tranche consists of cash subscriptions for 533,334 Class A shares at $15.00 per share, generating approximately $8.0 million in gross cash proceeds before fees and expenses. The second tranche involves the automatic conversion of a $2.0 million unsecured convertible promissory note, dated http://www.streetinsider.com/Equity+Offerings/Apollomics+announces+%2410M+private+placement+of+Class+A+shares/26906445.html Tue, 11 Aug 2026 16:35:53 -0400 APLM APLMW O.53171576 http://www.streetinsider.com/Equity+Offerings/Apollomics+announces+%2410M+private+placement+of+Class+A+shares/26906445.html <p>Apollomics Inc. (NASDAQ: APLM) has entered into definitive subscription agreements for a private placement of approximately $10.0 million, with closing expected on or about Aug. 14, 2026, subject to customary closing conditions.</p> <p>The transaction involves the issuance of up to 700,001 Class A ordinary shares at a par value of $0.01 per share, structured in two tranches. The first tranche consists of cash subscriptions for 533,334 Class A shares at $15.00 per share, generating approximately $8.0 million in gross cash proceeds before fees and expenses. The second tranche involves the automatic conversion of a $2.0 million unsecured convertible promissory note, dated http://www.streetinsider.com/Equity+Offerings/Apollomics+announces+%2410M+private+placement+of+Class+A+shares/26906445.html Tue, 11 Aug 2026 16:35:53 -0400 APLM APLMW O.53171576 http://www.streetinsider.com/Press+Releases/Apollomics+Announces+%2410+Million+Private+Placement+Transaction/26906444.html <p align="justify">FOSTER CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jmbkzViEk1AksZYMi6QErkKAE8iZ4NMYKgh6XHTLovC9H1OXsPg1NMzA0-hkR6Iu_JYW4i4dBWaP46FE0BeX7MSPUEk8CQQqRGTz4mUshak=" rel="nofollow" target="_blank">Apollomics Inc.</a> (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-35AxtOeT02VqEq0XdstCTy6Y_zK0SWfvGm-njpUiKFwamL_pTdXhDoO2goOLmsTXjVdL3AuhMtkZX-P9y2xIw8ANM03yaqJ74ZCmd5Wzv9_ufzYOrfLKeKOK1_XYLrS" rel="nofollow" target="_blank">APLM</a>) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that it has entered into definitive subscription agreements (the “Subscription Agreements”) for a private placement transaction (the “Private Placement”) with certain accredited investors (the “Investors”), for an aggregate gross consideration of approximately $10.0 million. The Private Placement is expected to close on or about August 14, 2026, subject to the satisfaction of customary closing http://www.streetinsider.com/Press+Releases/Apollomics+Announces+%2410+Million+Private+Placement+Transaction/26906444.html Tue, 11 Aug 2026 16:35:00 -0400 APLM APLMW O.53171576 http://www.streetinsider.com/Press+Releases/Apollomics+Announces+%2410+Million+Private+Placement+Transaction/26906444.html <p align="justify">FOSTER CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jmbkzViEk1AksZYMi6QErkKAE8iZ4NMYKgh6XHTLovC9H1OXsPg1NMzA0-hkR6Iu_JYW4i4dBWaP46FE0BeX7MSPUEk8CQQqRGTz4mUshak=" rel="nofollow" target="_blank">Apollomics Inc.</a> (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-35AxtOeT02VqEq0XdstCTy6Y_zK0SWfvGm-njpUiKFwamL_pTdXhDoO2goOLmsTXjVdL3AuhMtkZX-P9y2xIw8ANM03yaqJ74ZCmd5Wzv9_ufzYOrfLKeKOK1_XYLrS" rel="nofollow" target="_blank">APLM</a>) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that it has entered into definitive subscription agreements (the “Subscription Agreements”) for a private placement transaction (the “Private Placement”) with certain accredited investors (the “Investors”), for an aggregate gross consideration of approximately $10.0 million. The Private Placement is expected to close on or about August 14, 2026, subject to the satisfaction of customary closing http://www.streetinsider.com/Press+Releases/Apollomics+Announces+%2410+Million+Private+Placement+Transaction/26906444.html Tue, 11 Aug 2026 16:35:00 -0400 APLM APLMW O.53171576 http://www.streetinsider.com/Press+Releases/Apollomics+Announces+%2410+Million+Private+Placement+Transaction/26906444.html <p align="justify">FOSTER CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jmbkzViEk1AksZYMi6QErkKAE8iZ4NMYKgh6XHTLovC9H1OXsPg1NMzA0-hkR6Iu_JYW4i4dBWaP46FE0BeX7MSPUEk8CQQqRGTz4mUshak=" rel="nofollow" target="_blank">Apollomics Inc.</a> (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-35AxtOeT02VqEq0XdstCTy6Y_zK0SWfvGm-njpUiKFwamL_pTdXhDoO2goOLmsTXjVdL3AuhMtkZX-P9y2xIw8ANM03yaqJ74ZCmd5Wzv9_ufzYOrfLKeKOK1_XYLrS" rel="nofollow" target="_blank">APLM</a>) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that it has entered into definitive subscription agreements (the “Subscription Agreements”) for a private placement transaction (the “Private Placement”) with certain accredited investors (the “Investors”), for an aggregate gross consideration of approximately $10.0 million. The Private Placement is expected to close on or about August 14, 2026, subject to the satisfaction of customary closing http://www.streetinsider.com/Press+Releases/Apollomics+Announces+%2410+Million+Private+Placement+Transaction/26906444.html Tue, 11 Aug 2026 16:35:00 -0400 APLM APLMW O.53171576 http://www.streetinsider.com/Globe+Newswire/Apollomics+Announces+%2410+Million+Private+Placement+Transaction/26906444.html <p align="justify">FOSTER CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jmbkzViEk1AksZYMi6QErkKAE8iZ4NMYKgh6XHTLovC9H1OXsPg1NMzA0-hkR6Iu_JYW4i4dBWaP46FE0BeX7MSPUEk8CQQqRGTz4mUshak=" rel="nofollow" target="_blank">Apollomics Inc.</a> (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-35AxtOeT02VqEq0XdstCTy6Y_zK0SWfvGm-njpUiKFwamL_pTdXhDoO2goOLmsTXjVdL3AuhMtkZX-P9y2xIw8ANM03yaqJ74ZCmd5Wzv9_ufzYOrfLKeKOK1_XYLrS" rel="nofollow" target="_blank">APLM</a>) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that it has entered into definitive subscription agreements (the “Subscription Agreements”) for a private placement transaction (the “Private Placement”) with certain accredited investors (the “Investors”), for an aggregate gross consideration of approximately $10.0 million. The Private Placement is expected to close on or about August 14, 2026, subject to the satisfaction of customary closing http://www.streetinsider.com/Globe+Newswire/Apollomics+Announces+%2410+Million+Private+Placement+Transaction/26906444.html Tue, 11 Aug 2026 16:35:00 -0400 APLM APLMW O.53171576 http://www.streetinsider.com/Globe+Newswire/Apollomics+Announces+%2410+Million+Private+Placement+Transaction/26906444.html <p align="justify">FOSTER CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jmbkzViEk1AksZYMi6QErkKAE8iZ4NMYKgh6XHTLovC9H1OXsPg1NMzA0-hkR6Iu_JYW4i4dBWaP46FE0BeX7MSPUEk8CQQqRGTz4mUshak=" rel="nofollow" target="_blank">Apollomics Inc.</a> (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-35AxtOeT02VqEq0XdstCTy6Y_zK0SWfvGm-njpUiKFwamL_pTdXhDoO2goOLmsTXjVdL3AuhMtkZX-P9y2xIw8ANM03yaqJ74ZCmd5Wzv9_ufzYOrfLKeKOK1_XYLrS" rel="nofollow" target="_blank">APLM</a>) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that it has entered into definitive subscription agreements (the “Subscription Agreements”) for a private placement transaction (the “Private Placement”) with certain accredited investors (the “Investors”), for an aggregate gross consideration of approximately $10.0 million. The Private Placement is expected to close on or about August 14, 2026, subject to the satisfaction of customary closing http://www.streetinsider.com/Globe+Newswire/Apollomics+Announces+%2410+Million+Private+Placement+Transaction/26906444.html Tue, 11 Aug 2026 16:35:00 -0400 APLM APLMW O.53171576 http://www.streetinsider.com/Globe+Newswire/Apollomics+Announces+%2410+Million+Private+Placement+Transaction/26906444.html <p align="justify">FOSTER CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jmbkzViEk1AksZYMi6QErkKAE8iZ4NMYKgh6XHTLovC9H1OXsPg1NMzA0-hkR6Iu_JYW4i4dBWaP46FE0BeX7MSPUEk8CQQqRGTz4mUshak=" rel="nofollow" target="_blank">Apollomics Inc.</a> (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-35AxtOeT02VqEq0XdstCTy6Y_zK0SWfvGm-njpUiKFwamL_pTdXhDoO2goOLmsTXjVdL3AuhMtkZX-P9y2xIw8ANM03yaqJ74ZCmd5Wzv9_ufzYOrfLKeKOK1_XYLrS" rel="nofollow" target="_blank">APLM</a>) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that it has entered into definitive subscription agreements (the “Subscription Agreements”) for a private placement transaction (the “Private Placement”) with certain accredited investors (the “Investors”), for an aggregate gross consideration of approximately $10.0 million. The Private Placement is expected to close on or about August 14, 2026, subject to the satisfaction of customary closing http://www.streetinsider.com/Globe+Newswire/Apollomics+Announces+%2410+Million+Private+Placement+Transaction/26906444.html Tue, 11 Aug 2026 16:35:00 -0400 APLM APLMW O.53171576 http://www.streetinsider.com/Press+Releases/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html <ul><li style="text-align:left;"><em>Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential.</em></li><li style="text-align:left;"><em>To date, more than 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials.</em></li><li style="text-align:left;"><em>Phase 2/3 IND submission for development of vebreltinib in combination with an EGFR inhibitor in the U.S. and select Asian countries for the treatment of NSCLC.</em><br/></li></ul> <p>FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=izxkXWzOHUxYAEZ4qIXzYKNJN17xHzjbedxZOEVpQFhu4Ndls-Pgtsf4RPjAC2QobUhOOpaBW2nzN0fKSVjfJYiK14SgbVNnVyYnjls-r_c=" rel="nofollow" target="_blank">Apollomics Inc.</a> (Nasdaq: APLM), a clinical-stage biopharmaceutical company advancing innovative oncology therapies to transform the treatment http://www.streetinsider.com/Press+Releases/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html Mon, 27 Apr 2026 08:00:00 -0400 A.06822034 APLM APLMW O.20026344 O.53171576 http://www.streetinsider.com/Press+Releases/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html <ul><li style="text-align:left;"><em>Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential.</em></li><li style="text-align:left;"><em>To date, more than 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials.</em></li><li style="text-align:left;"><em>Phase 2/3 IND submission for development of vebreltinib in combination with an EGFR inhibitor in the U.S. and select Asian countries for the treatment of NSCLC.</em><br/></li></ul> <p>FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=izxkXWzOHUxYAEZ4qIXzYKNJN17xHzjbedxZOEVpQFhu4Ndls-Pgtsf4RPjAC2QobUhOOpaBW2nzN0fKSVjfJYiK14SgbVNnVyYnjls-r_c=" rel="nofollow" target="_blank">Apollomics Inc.</a> (Nasdaq: APLM), a clinical-stage biopharmaceutical company advancing innovative oncology therapies to transform the treatment http://www.streetinsider.com/Press+Releases/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html Mon, 27 Apr 2026 08:00:00 -0400 A.06822034 APLM APLMW O.20026344 O.53171576 http://www.streetinsider.com/Press+Releases/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html <ul><li style="text-align:left;"><em>Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential.</em></li><li style="text-align:left;"><em>To date, more than 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials.</em></li><li style="text-align:left;"><em>Phase 2/3 IND submission for development of vebreltinib in combination with an EGFR inhibitor in the U.S. and select Asian countries for the treatment of NSCLC.</em><br/></li></ul> <p>FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=izxkXWzOHUxYAEZ4qIXzYKNJN17xHzjbedxZOEVpQFhu4Ndls-Pgtsf4RPjAC2QobUhOOpaBW2nzN0fKSVjfJYiK14SgbVNnVyYnjls-r_c=" rel="nofollow" target="_blank">Apollomics Inc.</a> (Nasdaq: APLM), a clinical-stage biopharmaceutical company advancing innovative oncology therapies to transform the treatment http://www.streetinsider.com/Press+Releases/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html Mon, 27 Apr 2026 08:00:00 -0400 A.06822034 APLM APLMW O.20026344 O.53171576 http://www.streetinsider.com/Press+Releases/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html <ul><li style="text-align:left;"><em>Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential.</em></li><li style="text-align:left;"><em>To date, more than 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials.</em></li><li style="text-align:left;"><em>Phase 2/3 IND submission for development of vebreltinib in combination with an EGFR inhibitor in the U.S. and select Asian countries for the treatment of NSCLC.</em><br/></li></ul> <p>FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=izxkXWzOHUxYAEZ4qIXzYKNJN17xHzjbedxZOEVpQFhu4Ndls-Pgtsf4RPjAC2QobUhOOpaBW2nzN0fKSVjfJYiK14SgbVNnVyYnjls-r_c=" rel="nofollow" target="_blank">Apollomics Inc.</a> (Nasdaq: APLM), a clinical-stage biopharmaceutical company advancing innovative oncology therapies to transform the treatment http://www.streetinsider.com/Press+Releases/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html Mon, 27 Apr 2026 08:00:00 -0400 A.06822034 APLM APLMW O.20026344 O.53171576 http://www.streetinsider.com/Press+Releases/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html <ul><li style="text-align:left;"><em>Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential.</em></li><li style="text-align:left;"><em>To date, more than 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials.</em></li><li style="text-align:left;"><em>Phase 2/3 IND submission for development of vebreltinib in combination with an EGFR inhibitor in the U.S. and select Asian countries for the treatment of NSCLC.</em><br/></li></ul> <p>FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=izxkXWzOHUxYAEZ4qIXzYKNJN17xHzjbedxZOEVpQFhu4Ndls-Pgtsf4RPjAC2QobUhOOpaBW2nzN0fKSVjfJYiK14SgbVNnVyYnjls-r_c=" rel="nofollow" target="_blank">Apollomics Inc.</a> (Nasdaq: APLM), a clinical-stage biopharmaceutical company advancing innovative oncology therapies to transform the treatment http://www.streetinsider.com/Press+Releases/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html Mon, 27 Apr 2026 08:00:00 -0400 A.06822034 APLM APLMW O.20026344 O.53171576 http://www.streetinsider.com/Globe+Newswire/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html <ul><li style="text-align:left;"><em>Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential.</em></li><li style="text-align:left;"><em>To date, more than 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials.</em></li><li style="text-align:left;"><em>Phase 2/3 IND submission for development of vebreltinib in combination with an EGFR inhibitor in the U.S. and select Asian countries for the treatment of NSCLC.</em><br/></li></ul> <p>FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=izxkXWzOHUxYAEZ4qIXzYKNJN17xHzjbedxZOEVpQFhu4Ndls-Pgtsf4RPjAC2QobUhOOpaBW2nzN0fKSVjfJYiK14SgbVNnVyYnjls-r_c=" rel="nofollow" target="_blank">Apollomics Inc.</a> (Nasdaq: APLM), a clinical-stage biopharmaceutical company advancing innovative oncology therapies to transform the treatment http://www.streetinsider.com/Globe+Newswire/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html Mon, 27 Apr 2026 08:00:00 -0400 A.06822034 APLM APLMW O.20026344 O.53171576 http://www.streetinsider.com/Globe+Newswire/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html <ul><li style="text-align:left;"><em>Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential.</em></li><li style="text-align:left;"><em>To date, more than 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials.</em></li><li style="text-align:left;"><em>Phase 2/3 IND submission for development of vebreltinib in combination with an EGFR inhibitor in the U.S. and select Asian countries for the treatment of NSCLC.</em><br/></li></ul> <p>FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=izxkXWzOHUxYAEZ4qIXzYKNJN17xHzjbedxZOEVpQFhu4Ndls-Pgtsf4RPjAC2QobUhOOpaBW2nzN0fKSVjfJYiK14SgbVNnVyYnjls-r_c=" rel="nofollow" target="_blank">Apollomics Inc.</a> (Nasdaq: APLM), a clinical-stage biopharmaceutical company advancing innovative oncology therapies to transform the treatment http://www.streetinsider.com/Globe+Newswire/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html Mon, 27 Apr 2026 08:00:00 -0400 A.06822034 APLM APLMW O.20026344 O.53171576 http://www.streetinsider.com/Globe+Newswire/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html <ul><li style="text-align:left;"><em>Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential.</em></li><li style="text-align:left;"><em>To date, more than 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials.</em></li><li style="text-align:left;"><em>Phase 2/3 IND submission for development of vebreltinib in combination with an EGFR inhibitor in the U.S. and select Asian countries for the treatment of NSCLC.</em><br/></li></ul> <p>FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=izxkXWzOHUxYAEZ4qIXzYKNJN17xHzjbedxZOEVpQFhu4Ndls-Pgtsf4RPjAC2QobUhOOpaBW2nzN0fKSVjfJYiK14SgbVNnVyYnjls-r_c=" rel="nofollow" target="_blank">Apollomics Inc.</a> (Nasdaq: APLM), a clinical-stage biopharmaceutical company advancing innovative oncology therapies to transform the treatment http://www.streetinsider.com/Globe+Newswire/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html Mon, 27 Apr 2026 08:00:00 -0400 A.06822034 APLM APLMW O.20026344 O.53171576 http://www.streetinsider.com/Globe+Newswire/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html <ul><li style="text-align:left;"><em>Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential.</em></li><li style="text-align:left;"><em>To date, more than 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials.</em></li><li style="text-align:left;"><em>Phase 2/3 IND submission for development of vebreltinib in combination with an EGFR inhibitor in the U.S. and select Asian countries for the treatment of NSCLC.</em><br/></li></ul> <p>FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=izxkXWzOHUxYAEZ4qIXzYKNJN17xHzjbedxZOEVpQFhu4Ndls-Pgtsf4RPjAC2QobUhOOpaBW2nzN0fKSVjfJYiK14SgbVNnVyYnjls-r_c=" rel="nofollow" target="_blank">Apollomics Inc.</a> (Nasdaq: APLM), a clinical-stage biopharmaceutical company advancing innovative oncology therapies to transform the treatment http://www.streetinsider.com/Globe+Newswire/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html Mon, 27 Apr 2026 08:00:00 -0400 A.06822034 APLM APLMW O.20026344 O.53171576 http://www.streetinsider.com/Globe+Newswire/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html <ul><li style="text-align:left;"><em>Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential.</em></li><li style="text-align:left;"><em>To date, more than 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials.</em></li><li style="text-align:left;"><em>Phase 2/3 IND submission for development of vebreltinib in combination with an EGFR inhibitor in the U.S. and select Asian countries for the treatment of NSCLC.</em><br/></li></ul> <p>FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=izxkXWzOHUxYAEZ4qIXzYKNJN17xHzjbedxZOEVpQFhu4Ndls-Pgtsf4RPjAC2QobUhOOpaBW2nzN0fKSVjfJYiK14SgbVNnVyYnjls-r_c=" rel="nofollow" target="_blank">Apollomics Inc.</a> (Nasdaq: APLM), a clinical-stage biopharmaceutical company advancing innovative oncology therapies to transform the treatment http://www.streetinsider.com/Globe+Newswire/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html Mon, 27 Apr 2026 08:00:00 -0400 A.06822034 APLM APLMW O.20026344 O.53171576 http://www.streetinsider.com/Press+Releases/Apollomics+Announces+Settlement+of+Cayman+Litigation/25639385.html <p>FOSTER CITY, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”) (Nasdaq: APLM) announced today entering into a settlement agreement (the “Settlement Agreement” or the “Agreement”) with TWVC Goldlink Partners Investment Limited and TWVC Panglin Group Investment Limited (together, “TWVC”), entities represented by Triwise Capital Management Ltd, in connection with the litigation previously filed in the Grand Court of the Cayman Islands (the “Cayman Litigation”). The Cayman Litigation involved claims by two minority shareholders relating to the requested redemption of preferred shares of the Company before the consummation of the Company’s merger with Maxpro http://www.streetinsider.com/Press+Releases/Apollomics+Announces+Settlement+of+Cayman+Litigation/25639385.html Wed, 19 Nov 2025 17:38:00 -0400 APLM APLMW O.53171576 http://www.streetinsider.com/Press+Releases/Apollomics+Announces+Settlement+of+Cayman+Litigation/25639385.html <p>FOSTER CITY, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”) (Nasdaq: APLM) announced today entering into a settlement agreement (the “Settlement Agreement” or the “Agreement”) with TWVC Goldlink Partners Investment Limited and TWVC Panglin Group Investment Limited (together, “TWVC”), entities represented by Triwise Capital Management Ltd, in connection with the litigation previously filed in the Grand Court of the Cayman Islands (the “Cayman Litigation”). The Cayman Litigation involved claims by two minority shareholders relating to the requested redemption of preferred shares of the Company before the consummation of the Company’s merger with Maxpro http://www.streetinsider.com/Press+Releases/Apollomics+Announces+Settlement+of+Cayman+Litigation/25639385.html Wed, 19 Nov 2025 17:38:00 -0400 APLM APLMW O.53171576 http://www.streetinsider.com/Press+Releases/Apollomics+Announces+Settlement+of+Cayman+Litigation/25639385.html <p>FOSTER CITY, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”) (Nasdaq: APLM) announced today entering into a settlement agreement (the “Settlement Agreement” or the “Agreement”) with TWVC Goldlink Partners Investment Limited and TWVC Panglin Group Investment Limited (together, “TWVC”), entities represented by Triwise Capital Management Ltd, in connection with the litigation previously filed in the Grand Court of the Cayman Islands (the “Cayman Litigation”). The Cayman Litigation involved claims by two minority shareholders relating to the requested redemption of preferred shares of the Company before the consummation of the Company’s merger with Maxpro http://www.streetinsider.com/Press+Releases/Apollomics+Announces+Settlement+of+Cayman+Litigation/25639385.html Wed, 19 Nov 2025 17:38:00 -0400 APLM APLMW O.53171576 http://www.streetinsider.com/Globe+Newswire/Apollomics+Announces+Settlement+of+Cayman+Litigation/25639385.html <p>FOSTER CITY, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”) (Nasdaq: APLM) announced today entering into a settlement agreement (the “Settlement Agreement” or the “Agreement”) with TWVC Goldlink Partners Investment Limited and TWVC Panglin Group Investment Limited (together, “TWVC”), entities represented by Triwise Capital Management Ltd, in connection with the litigation previously filed in the Grand Court of the Cayman Islands (the “Cayman Litigation”). The Cayman Litigation involved claims by two minority shareholders relating to the requested redemption of preferred shares of the Company before the consummation of the Company’s merger with Maxpro http://www.streetinsider.com/Globe+Newswire/Apollomics+Announces+Settlement+of+Cayman+Litigation/25639385.html Wed, 19 Nov 2025 17:38:00 -0400 APLM APLMW O.53171576 http://www.streetinsider.com/Globe+Newswire/Apollomics+Announces+Settlement+of+Cayman+Litigation/25639385.html <p>FOSTER CITY, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”) (Nasdaq: APLM) announced today entering into a settlement agreement (the “Settlement Agreement” or the “Agreement”) with TWVC Goldlink Partners Investment Limited and TWVC Panglin Group Investment Limited (together, “TWVC”), entities represented by Triwise Capital Management Ltd, in connection with the litigation previously filed in the Grand Court of the Cayman Islands (the “Cayman Litigation”). The Cayman Litigation involved claims by two minority shareholders relating to the requested redemption of preferred shares of the Company before the consummation of the Company’s merger with Maxpro http://www.streetinsider.com/Globe+Newswire/Apollomics+Announces+Settlement+of+Cayman+Litigation/25639385.html Wed, 19 Nov 2025 17:38:00 -0400 APLM APLMW O.53171576 http://www.streetinsider.com/Globe+Newswire/Apollomics+Announces+Settlement+of+Cayman+Litigation/25639385.html <p>FOSTER CITY, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”) (Nasdaq: APLM) announced today entering into a settlement agreement (the “Settlement Agreement” or the “Agreement”) with TWVC Goldlink Partners Investment Limited and TWVC Panglin Group Investment Limited (together, “TWVC”), entities represented by Triwise Capital Management Ltd, in connection with the litigation previously filed in the Grand Court of the Cayman Islands (the “Cayman Litigation”). The Cayman Litigation involved claims by two minority shareholders relating to the requested redemption of preferred shares of the Company before the consummation of the Company’s merger with Maxpro http://www.streetinsider.com/Globe+Newswire/Apollomics+Announces+Settlement+of+Cayman+Litigation/25639385.html Wed, 19 Nov 2025 17:38:00 -0400 APLM APLMW O.53171576